Kiniksa Pharmaceuticals, Ltd.
KNSA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2,858 | $2,032 | $1,613 | $1,430 |
| - Cash | $175 | $192 | $157 | $184 |
| + Debt | $10 | $10 | $10 | $10 |
| Enterprise Value | $2,693 | $1,850 | $1,466 | $1,257 |
| Revenue | $181 | $157 | $138 | $123 |
| % Growth | 15.3% | 13.8% | 12.4% | – |
| Gross Profit | $97 | $86 | $76 | $56 |
| % Margin | 53.8% | 54.7% | 55.3% | 46% |
| EBITDA | $28 | $21 | $14 | -$17 |
| % Margin | 15.2% | 13.1% | 9.9% | -13.5% |
| Net Income | $18 | $18 | $9 | -$9 |
| % Margin | 10.2% | 11.4% | 6.2% | -7.3% |
| EPS Diluted | 0.23 | 0.23 | 0.11 | -0.12 |
| % Growth | 0% | 109.1% | 191.7% | – |
| Operating Cash Flow | $34 | $28 | $22 | $19 |
| Capital Expenditures | -$1 | -$0 | -$0 | -$0 |
| Free Cash Flow | $33 | $28 | $22 | $19 |